The abuse of opioids continues to have a devastating effect throughout the United States, as 2 recent studies highlight.
Howard Koh, MD, MPH
The first study, a national poll by the Harvard T. H. Chan School of Public Health and the Boston Globe, found that about 40% of respondents personally knew someone who had abused or misused prescription pain medicines such as hydrocodone in the past 45 years (http://bit.ly/1JHYqtd). Only about 45% believed that long-lasting treatment was effective for opioid dependency.
The second study, from the Centers for Disease Control and Prevention and the Food and Drug Administration (FDA), found that heroin abuse, traditionally more common among men and the poor, is now rising rapidly in groups such as women, the privately insured, and those of higher income (http://1.usa.gov/1Fo8QtT).
These findings represent just the tip of the iceberg. From 2001-2013, the annual number of overdose deaths rose 3-fold for prescription opioid analgesics (to more than 16 200) and 5-fold for heroin (to more than 8200 deaths) (http://1.usa.gov/1znaUDW). Such trends parallel the steady increase in opioid analgesics to 259 million prescriptions a year, enough for each American adult (http://1.usa.gov/1JFmWJg).
People can readily access and misuse legal drugs in the medicine cabinet prescribed for others. Three-quarters of new users of heroin, a cheaper and more readily available opioid, initially began using prescription painkillers for nonmedical reasons. Researchers cite additional factors, such as aggressive pain treatment as a desired feature of quality care, availability of new formulations, pharmaceutical marketing, and previous underappreciation of addiction risk by professionals and public alike, as contributing to these trends.
Currently, nearly 2 million people abuse or are dependent on prescription opioids and more than half a million abuse or are dependent on heroin (http://1.usa.gov/1rpXmxJ). Multiple drug use, involving alcohol and sedatives for example, can increase overdose risk. Further complicating the picture are HIV and hepatitis C associated with intravenous use.
The crisis has triggered a dramatic response nationwide. Federal agencies, such as the White House Office of National Drug Control Policy (ONDCP) and the US Department of Health and Human Services, have offered comprehensive strategies to prevent opioid abuse and overdose. State and local leaders, including elected officials, have led a surge of community activity on the following fronts:
Clinicians are striving for a finer balance that meets the patient’s need for pain relief while minimizing chances for abuse. Updated professional education efforts promote state-based and specialty society-based prescribing guidelines that encourage separate treatment approaches for acute and chronic pain; careful consideration of abuse risk before prescribing; “contracts” that clarify expectations, goals, and responsibilities for patients and prescribers; and use of the lowest effective dose for the shortest possible duration.
In addition, community public education efforts have encouraged safer disposal of unused medicines from the home. Research to reduce the supply of unsafe analgesics has prioritized creating deterrent forms of pills that cannot be crushed and abused, as well as novel painkillers with little or no abuse potential.
Prescription drug monitoring programs (PDMPs), which electronically track prescriptions of all controlled drugs, now operate in 49 states (except Missouri) and Washington, DC (http://nyti.ms/1u8aKxQ). PDMPs can identify possible nonmedical use and diversion. Physicians can connect to them as part of prescribing while pharmacists can check them before dispensing.
A preliminary analysis of mandated PDMP use in Kentucky, Tennessee, and New York showed fewer episodes of patients seeking prescription opioids from multiple providers (http://bit.ly/1IP9kJP). Nonetheless, many PDMPs still need substantial improvements to reach the ideal in which they are easy to use, offer standardized content, update information in real time, and demonstrate interstate accessibility. Also, a new national initiative pairs law enforcement with public health officials to better trace and monitor trafficking of heroin, which in some states is now often laced with fentanyl, a powerful synthetic opioid.
Naloxone (Narcan), which temporarily reverses the respiratory depression associated with opiate overdose, can prevent opioid-related death. Although it is traditionally administered intravenously in the medical setting, the availability of an intranasal formulation now allows ready use in the field by laypersons and first responders—fire and police department personnel.
A recent survey notes that expanded naloxone use by laypersons, viewed as safe and cost-effective, has now reached 30 states and Washington, DC (http://1.usa.gov/1NgErFz). In 2014, the FDA approved a naloxone autoinjector that could further expand usage.
Tocounter public misperceptions about treatment futility, ONDCP Director Michael Botticelli, MEd, emphasizes showing “hope on the other side” of addiction (http://bit.ly/1OiADRA). Citing his personal perspective as a person in recovery, Botticelli promotes the proven value of linking people to care through a continuum of services, including medication-assisted treatment (including buprenorphine, methadone, and naltrexone), counseling, and behavioral therapy. Promising approaches also include using the emergency department setting to initiate buprenorphine for opioid-dependent patients (as opposed to brief intervention and referral), as well as to connect with recovery coaches (http://bit.ly/1bSDRxm).
Long-term success requires substantially improving treatment capacity that has been chronically underresourced with respect to facilities and trained clinicians. The Affordable Care Act (2010) and the Mental Health Parity and Addiction Equity Act (2008) offer major opportunities to improve insurance coverage and treatment, but barriers for smooth implementation remain. Meanwhile, community-based coalitions, involving local schools, youth groups, law enforcement and faith-based organizations, among others, have heightened public education about the power of prevention.
Media stories about how the opioid crisis cuts short promising lives are renewing public attention, commitment, and concern. Viewing substance use disorders as a chronic disease that waxes and wanes, not as a moral failing, may help overcome stigma that prevents affected people from seeking treatment. Encouraging public dialogue that refers to a “person with a substance use disorder” (instead of “addict”) and “person in recovery” (instead of “former addict”) can medicalize what many still view as primarily a criminal problem.
The heightened national response to the current opioid crisis, although noteworthy, must be deepened and sustained. Although prescription opioid-related deaths have leveled in the last several years, the country has not yet documented the progress seen with other substance abuse areas, such as tobacco dependence and underage drinking. Overcoming the opioid crisis will require the highest level of commitment of communities, clinicians, public health, and public safety for many years to come.
Corresponding Author: Howard Koh, MD, MPH (email@example.com)
Published online: September 2, 2015, at http//:newsatjama.jama.com/category/the-jama-forum/.
Disclaimer: Each entry in The JAMA Forum expresses the opinions of the author but does not necessarily reflect the views or opinions of JAMA, the editorial staff, or the American Medical Association.
Additional Information: Information about The JAMA Forum is available at http://newsatjama.jama.com/about/. Information about disclosures of potential conflicts of interest may be found at http://newsatjama.jama.com/jama-forum-disclosures/.
Koh H. Community Approaches to the Opioid Crisis. JAMA. 2015;314(14):1437-1438. doi:10.1001/jama.2015.12346